Gottlieb condemns ‘rigged payment scheme’ for biosimilar drugs
Scott Gottlieb says the way biosimilar drugs are paid for is "rigged" — ultimately, keeping them out of patients' reach.
WASHINGTON — Food and Drug Administration Commissioner Scott Gottlieb said that it’s not his agency’s job to regulate drug prices — but on Wednesday morning, he used his bully pulpit to condemn a “rigged payment scheme” that he said he fears is keeping some generic drugs out of the market.
Speaking to a group of hundreds at a conference run manufacturers, which make generic biologic drugs. He called on the audience primarily of insurance professionals to do something, offering a few concrete suggestions.
